How Primary Care Can Screen and Treat Chronic Kidney Disease in People with Type 2 Diabetes

Conflict of Interest EEW is on the speakers’ bureau for Abbott Diabetes, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, and Sanofi; is on the advisory boards of Abbott Diabetes, Bayer, Boehringer Ingelheim, Eli Lilly, Medtronic, and Sanofi; is a consultant for Abbott Diabetes, Bayer, Boehringer Ingelheim, and Eli Lilly; and is an Associate Editor of Clinical Diabetes. AC is an advisor on scientific boards for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, and Novo Nordisk; lectures for AstraZeneca, Boehringer Ingelheim, Esteve, Janssen, Eli Lilly, Merck Sharp & Dohme, Mundipharma, and Novo Nordisk; and conducts research activities for AstraZeneca, Merck Sharp & Dohme, Mundipharma, Novo Nordisk, and Eli Lilly. DN is a member of the advisory board for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; has moderating and speaking engagements for AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; has participated in research in the FINE-REAL trial and Pioneer REAL trials, and is a member of the Diabetes Canada Guidelines Steering Committee, Canadian Cardiovascular Society Lipid Guideline Panel, and St. Paul’s Hospital Continued Medical Education (CME) Committee.